Patients with intermediate-risk (PSA 10–20 ng/ml or Gleason score 7 or cT2b) or high-risk (PSA >20 ng/ml or Gleason score 8–10 or cT2c/3/4) prostate cancer are advised to have a staging baseline bone scan. This evidence concerns the gene KLK3 and prostate cancer.